Gopa Iyer
YOU?
Author Swipe
View article: Supplementary Data 1 from Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer
Supplementary Data 1 from Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer Open
Supplementary Tables and Figures
View article: Supplementary Table S1 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer
Supplementary Table S1 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer Open
Supplementary Table S1
View article: Supplementary Data 1 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer
Supplementary Data 1 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer Open
List of TCGA cases used in ATAC-seq analysis
View article: Supplementary Figure Legends from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer
Supplementary Figure Legends from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer Open
Supplementary Figure Legends
View article: Supplementary Figure 5 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer
Supplementary Figure 5 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer Open
Supplementary Figure 5
View article: Supplementary Figure 2 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer
Supplementary Figure 2 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer Open
Supplementary Figure 2
View article: Supplementary Figure 1 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer
Supplementary Figure 1 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer Open
Supplementary Figure 1
View article: Supplementary Figure 3 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer
Supplementary Figure 3 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer Open
Supplementary Figure 3
View article: Supplementary Data 2 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer
Supplementary Data 2 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer Open
ATF3 target genes downregulated in K2 that harbor FOXA1 peaks in RT4
View article: Supplementary Figure 7 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer
Supplementary Figure 7 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer Open
Supplementary Figure 7
View article: Combination Strategies to Enhance Bacillus Calmette–Guérin Efficacy for Non-Muscle Invasive Bladder Cancer
Combination Strategies to Enhance Bacillus Calmette–Guérin Efficacy for Non-Muscle Invasive Bladder Cancer Open
BCG-based combination therapies have emerged as a strategy to overcome BCG resistance and promote durable responses. Despite their promise, combination design is endless, and adoption remains challenging due to overlapping mechanisms of re…
View article: 1318 Phase 1 clinical data show FX-909, a first-in-class oral PPARG inhibitor, drives immune modulation and pro-inflammatory cytokine induction in IO-experienced patients with advanced urothelial carcinoma
1318 Phase 1 clinical data show FX-909, a first-in-class oral PPARG inhibitor, drives immune modulation and pro-inflammatory cytokine induction in IO-experienced patients with advanced urothelial carcinoma Open
View article: Quantitative functional profiling of ERCC2 mutations deciphers cisplatin sensitivity in bladder cancer
Quantitative functional profiling of ERCC2 mutations deciphers cisplatin sensitivity in bladder cancer Open
Tumor gene alterations can serve as predictive biomarkers for therapy response. The nucleotide excision repair (NER) helicase ERCC2 carries heterozygous missense mutations in approximately 10% of bladder tumors, and these may predict sensi…
View article: Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma
Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma Open
Along with previously published safety data, EV+P demonstrated benefit compared with chemotherapy across all prespecified subgroups, consistent with the ITT population and supporting EV+P as the standard of care for first-line treatment of…
View article: Dupilumab for bullous pemphigoid related to immune checkpoint inhibitors: a retrospective case series
Dupilumab for bullous pemphigoid related to immune checkpoint inhibitors: a retrospective case series Open
Background Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy but are associated with treatment-limiting immune-related cutaneous adverse events (irCAEs). Immune checkpoint inhibitor-related bullous pemphigoid (irBP), a…
View article: The Dublin International Society of Urological Pathology (ISUP) Consensus Conference on Best Practice Recommendations on the Pathology of Urachal Neoplasms
The Dublin International Society of Urological Pathology (ISUP) Consensus Conference on Best Practice Recommendations on the Pathology of Urachal Neoplasms Open
This manuscript summarizes the first part of the proceedings of the 2023 Dublin ISUP Consensus Conference encompassing the best practice recommendations on the pathology of neoplasms of urachal origin. The rationale for convening this cons…
View article: Nonoperative Management of Mismatch Repair–Deficient Tumors
Nonoperative Management of Mismatch Repair–Deficient Tumors Open
Among patients with early-stage dMMR solid tumors that were amenable to curative-intent surgery, neoadjuvant PD-1 blockade led to organ preservation in a high proportion of patients. (Funded by Swim Across America and others; ClinicalTrial…
View article: Immune Checkpoint Blockade Response in Mucinous Tubular and Spindle Cell Carcinoma
Immune Checkpoint Blockade Response in Mucinous Tubular and Spindle Cell Carcinoma Open
Mucinous tubular and spindle cell carcinoma (MTSCC) is a rare kidney tumor which is usually characterized by indolent disease physiology. While several high-grade and sarcomatoid MTSCC tumors have been reported, the clinical experience wit…
View article: A study to learn how well enfortumab vedotin (EV) with pembrolizumab works and how safe it is in people with advanced urothelial cancer: a plain language summary of the EV-302/KEYNOTE-A39 study
A study to learn how well enfortumab vedotin (EV) with pembrolizumab works and how safe it is in people with advanced urothelial cancer: a plain language summary of the EV-302/KEYNOTE-A39 study Open
What is this summary about? This is a summary of the publication of the EV-302/KEYNOTE-A39 study that was published in The New England Journal of Medicine in March 2024. The study helped researchers learn more about a possible new treatmen…
View article: Loss of Kmt2c or Kmt2d primes urothelium for tumorigenesis and redistributes KMT2A–menin to bivalent promoters
Loss of Kmt2c or Kmt2d primes urothelium for tumorigenesis and redistributes KMT2A–menin to bivalent promoters Open
View article: Molecular Heterogeneity and Immune Infiltration Drive Clinical Outcomes in Upper Tract Urothelial Carcinoma
Molecular Heterogeneity and Immune Infiltration Drive Clinical Outcomes in Upper Tract Urothelial Carcinoma Open
View article: Supplementary Figure 9 from Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guérin Immunotherapy in Non–Muscle-Invasive Bladder Cancer
Supplementary Figure 9 from Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guérin Immunotherapy in Non–Muscle-Invasive Bladder Cancer Open
Supplemental Figure 9A demonstrates the overlap between "p53-associated" signature from Troester et al. vs. "p53-like" signature from Choi et al; Supplemental Figure 9B shows the "p53-like" signature from Choi et (MDA) by UROMOL Subclasses…
View article: Supplementary Figure 11 from Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guérin Immunotherapy in Non–Muscle-Invasive Bladder Cancer
Supplementary Figure 11 from Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guérin Immunotherapy in Non–Muscle-Invasive Bladder Cancer Open
Supplemental Figure 11 shows the correlation between P53 Score by immune score, FOXM1 expression, Proliferation marker expression.
View article: Data from Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guérin Immunotherapy in Non–Muscle-Invasive Bladder Cancer
Data from Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guérin Immunotherapy in Non–Muscle-Invasive Bladder Cancer Open
Purpose:Improved risk stratification and predictive biomarkers of treatment response are needed for non–muscle-invasive bladder cancer (NMIBC). Here we assessed the clinical utility of targeted RNA and DNA molecular profiling in NMIBC.Expe…
View article: Supplementary Figure 6 from Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guérin Immunotherapy in Non–Muscle-Invasive Bladder Cancer
Supplementary Figure 6 from Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guérin Immunotherapy in Non–Muscle-Invasive Bladder Cancer Open
Supplemental Figure 6 shows Recurrence Free Survival in the Northwestern HGT1 cohort by immune score stratified by (1) High, Medium, Low; (2) High/Medium vs. Low.
View article: Supplementary Figure 5 from Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guérin Immunotherapy in Non–Muscle-Invasive Bladder Cancer
Supplementary Figure 5 from Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guérin Immunotherapy in Non–Muscle-Invasive Bladder Cancer Open
Supplemental Figure 5 shows immune score signature using the publicly available UROMOL.
View article: Supplementary Figure 8 from Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guérin Immunotherapy in Non–Muscle-Invasive Bladder Cancer
Supplementary Figure 8 from Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guérin Immunotherapy in Non–Muscle-Invasive Bladder Cancer Open
Supplemental Figure 8 shows the relationship between the Fraction of Genome Altered by UROMOL subgroups within the MSK cohort.
View article: Supplementary Figure 3 from Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guérin Immunotherapy in Non–Muscle-Invasive Bladder Cancer
Supplementary Figure 3 from Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guérin Immunotherapy in Non–Muscle-Invasive Bladder Cancer Open
Supplemental Figure 3 shows the relationship for UROMOL Subclasses in MSK and UNC cohorts between expression of Proliferation markers and FOXM1.
View article: Supplementary Figure 7 from Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guérin Immunotherapy in Non–Muscle-Invasive Bladder Cancer
Supplementary Figure 7 from Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guérin Immunotherapy in Non–Muscle-Invasive Bladder Cancer Open
Supplemental Figure 7 shows PDL1 (CD274) Expression, PD1 (PDCD1) Expression, and CTLA4 Expression by UROMOL Subclasses in MSK and UNC cohorts and RFS (by high, medium, low tertiles) in MSK, UROMOL, & Northwestern Cohorts.
View article: Supplementary Figure 4 from Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guérin Immunotherapy in Non–Muscle-Invasive Bladder Cancer
Supplementary Figure 4 from Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guérin Immunotherapy in Non–Muscle-Invasive Bladder Cancer Open
Supplemental Figure 4 shows the relationship between Immune Signature score by Patient Cohort and UROMOL subtype.